Malaria Pregnancy and Childbirth
Conditions
Interventions
artemether-lumefantrine
Sponsors
Marcel Ukah
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: a)Microscopically-confirmed P. falciparum malaria with parasitaemia of atleast one plus(1-10 parasites /100 thick film field). b)Fever (T of 37.50C) or a history of fever,headaches,body pains within 24 hours of presentation c)Ability to give informed consent d)Willingness/ability to comply with follow up visits.
Exclusion criteria
Exclusion criteria: a)Severe malaria or danger signs of severe malaria (e.g. loss of consciousness, convulsions, anuria) b)Women in the first 13 weeks of pregnancy i.e. 1st trimester c)Use of any anti-malarial drug other than sulphadoxine pyrimethamine less than 7 days before presentation d)Other chronic illness e.g. hypertension, sickle cell. e)Other pregnancy related diseases e.g. eclampsia, antepartum hemorrhage f)History of reaction to any of the study drugs g)Patients not tolerating orally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy, safety and tolerability of Artesunate-Amodiaquine fixed dose combination compared to the Artemether-Lumefantrine fixed dose combination in the treatment of acute uncomplicated P. falciparum malaria in pregnancy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Describe the pregnancy outcome in these women | — |
Countries
Nigeria
Contacts
Public ContactMarcel Ukah
Outcome results
None listed